SIGLEC1 and glioma: Administration of anti-NK1.1 antibody to deplete NK cells reduced CD169 expression in tumors (Fig. 5e), suggesting that IFN-γ produced by NK cells is required for the infiltration of CD169+ macrophages into gliomas.